Search research articles
Contact Us
Filters
Showing results (51-60 of 84) with videos related to
Page
of 9
Sort By:
Journal of Surgical Oncology
|
October 31, 2009
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer
C S Boskos, C Liacos, D Korkolis, et al.
BMC Urology
|
June 4, 2020
Axitinib as a third or further line of treatment in renal cancer: a single institution experience
G Tsironis, M Liontos, A Kyriazoglou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2011
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor
A Bamias, M Sotiropoulou, F Zagouri, et al.
Bone Marrow Transplantation
|
November 21, 2007
High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial
C Papadimitriou, U Dafni, A Anagnostopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2005
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group
N Xiros, P Papacostas, T Economopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
September 29, 2007
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
E Briasoulis, G Fountzilas, A Bamias, et al.
Anticancer Research
|
August 30, 2008
Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study
A Bamias, F Kyriakou, M Chorti, et al.
Anticancer Research
|
April 1, 2009
Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG)
D Pectasides, G Papaxoinis, G Fountzilas, et al.
British Journal of Cancer
|
October 18, 2007
Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications
H Gakiopoulou, P Korkolopoulou, G Levidou, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 84) with videos related to
Sort By:
Page
of 9
Journal of Surgical Oncology
|
October 31, 2009
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer
C S Boskos, C Liacos, D Korkolis, et al.
BMC Urology
|
June 4, 2020
Axitinib as a third or further line of treatment in renal cancer: a single institution experience
G Tsironis, M Liontos, A Kyriazoglou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2011
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor
A Bamias, M Sotiropoulou, F Zagouri, et al.
Bone Marrow Transplantation
|
November 21, 2007
High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial
C Papadimitriou, U Dafni, A Anagnostopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2005
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group
N Xiros, P Papacostas, T Economopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
September 29, 2007
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
E Briasoulis, G Fountzilas, A Bamias, et al.
Anticancer Research
|
August 30, 2008
Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study
A Bamias, F Kyriakou, M Chorti, et al.
Anticancer Research
|
April 1, 2009
Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG)
D Pectasides, G Papaxoinis, G Fountzilas, et al.
British Journal of Cancer
|
October 18, 2007
Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications
H Gakiopoulou, P Korkolopoulou, G Levidou, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Page
of 9